Our Statement on Recent Talc Verdict
COVID-19 Update: Your Latest Questions About Johnson & Johnson's Investigational Vaccine Candidate AnsweredDid you like reading this story? Click the heart to show your love.
The COVID-19 Data Plan: 3 Innovative Ways Johnson & Johnson Is Using Data Science to Fight the PandemicDid you like reading this story? Click the heart to show your love.
A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine CandidateDid you like reading this message? Click the heart to show your love.
"We deeply sympathize with the women and families impacted by ovarian cancer. We will begin the appeals process following today’s verdict and believe a jury decision in our favor in St. Louis in March and the dismissal of two cases in New Jersey in September 2016 by a state court judge who ruled that plaintiffs’ scientific experts could not adequately support their theories that talcum powder causes ovarian cancer, further highlight the lack of credible scientific evidence behind plaintiffs’ allegations. We are preparing for additional trials this year and we will continue to defend the safety of Johnson’s Baby Powder." - Carol Goodrich, Global Media Relations, Johnson & Johnson Consumer, Inc.
For more information, please also see: 5 Important Facts About the Safety of Talc